z-logo
Premium
Aβ seeding potency peaks in the early stages of cerebral β‐amyloidosis
Author(s) -
Ye Lan,
Rasmussen Jay,
Kaeser Stephan A,
Marzesco AnneMarie,
Obermüller Ulrike,
Mahler Jasmin,
Schelle Juliane,
Odenthal Jörg,
Krüger Christian,
Fritschi Sarah K,
Walker Lary C,
Staufenbiel Matthias,
Baumann Frank,
Jucker Mathias
Publication year - 2017
Publication title -
embo reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.584
H-Index - 184
eISSN - 1469-3178
pISSN - 1469-221X
DOI - 10.15252/embr.201744067
Subject(s) - german , graduate students , library science , brain research , research center , neuroscience , medicine , psychology , history , medical education , computer science , pathology , archaeology
Abstract Little is known about the extent to which pathogenic factors drive the development of Alzheimer's disease ( AD ) at different stages of the long preclinical and clinical phases. Given that the aggregation of the β‐amyloid peptide (Aβ) is an important factor in AD pathogenesis, we asked whether Aβ seeds from brain extracts of mice at different stages of amyloid deposition differ in their biological activity. Specifically, we assessed the effect of age on Aβ seeding activity in two mouse models of cerebral Aβ amyloidosis ( APPPS 1 and APP 23) with different ages of onset and rates of progression of Aβ deposition. Brain extracts from these mice were serially diluted and inoculated into host mice. Strikingly, the seeding activity (seeding dose SD 50 ) in extracts from donor mice of both models reached a plateau relatively early in the amyloidogenic process. When normalized to total brain Aβ, the resulting specific seeding activity sharply peaked at the initial phase of Aβ deposition, which in turn is characterized by a temporary several‐fold increase in the Aβ42/Aβ40 ratio. At all stages, the specific seeding activity of the APPPS 1 extract was higher compared to that of APP 23 brain extract, consistent with a more important contribution of Aβ42 than Aβ40 to seed activity. Our findings indicate that the Aβ seeding potency is greatest early in the pathogenic cascade and diminishes as Aβ increasingly accumulates in brain. The present results provide experimental support for directing anti‐Aβ therapeutics to the earliest stage of the pathogenic cascade, preferably before the onset of amyloid deposition.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here